INT201128

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.13
First Reported 2007
Last Reported 2007
Negated 0
Speculated 1
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 0.20
Pain Relevance 0.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (QRFPR) signal transducer activity (QRFPR)
QRFPR (Homo sapiens)
Pain Link Frequency Relevance Heat
pruritus 4 53.16 Quite High
abdominal pain 2 22.48 Low Low
headache 14 5.00 Very Low Very Low Very Low
Bioavailability 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Toxicity 14 79.96 Quite High
Pruritus 4 53.16 Quite High
Fatigue 4 49.96 Quite Low
Exanthema 4 46.08 Quite Low
Anorexia 2 23.20 Low Low
Abdominal Pain 2 22.48 Low Low
Vomiting 10 21.84 Low Low
Diarrhoea 6 21.44 Low Low
Dizziness 20 10.20 Low Low
Malaria 36 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The two volunteers who received AQ-13 had received the 100 and 300 mg doses; the two volunteers who received CQ had both received the 1,500 mg dose.
Regulation (received) of AQ-13
1) Confidence 0.13 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.20 Pain Relevance 0.03
When the effects of AQ-13 and CQ were analyzed by gender, QTc prolongation was significant only for females after the 600 and 700 mg doses.
Spec (analyzed) Regulation (effects) of AQ-13
2) Confidence 0.08 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox